Abstract:Type 2 diabetes (T2D), one of the most common diseases in the western world, is characterized by insulin resistance and impaired beta-cell function but currently it is difficult to determine the precise pathophysiology in individual T2D patients. Non-targeted metabolomics technologies have the potential for providing novel biomarkers of disease and drug efficacy, and are increasingly being incorporated into biomarker exploration studies. Contextualization of metabolomics results is enhanced by integration of study data from other platforms, such as transcriptomics, thus linking known metabolites and genes to relevant biochemical pathways. In the current study, urinary NMR-based metabolomic and liver, adipose, and muscle transcriptomic results from the db/db diabetic mouse model are described. To assist with cross-platform integration, integrative pathway analysis was used. Sixty-six metabolites were identified in urine that discriminate between the diabetic db/db and control db/+ mice. The combined analysis of metabolite and gene expression changes revealed 24 distinct pathways that were altered in the diabetic model. Several of these pathways are related to expected diabetes-related changes including changes in lipid metabolism, gluconeogenesis, mitochondrial dysfunction and oxidative stress, as well as protein and amino acid metabolism. Novel findings were also observed, particularly related to the metabolism of branched chain amino acids (BCAAs), nicotinamide metabolites, and pantothenic acid. In particular, the observed decrease in urinary BCAA catabolites provides direct corroboration of previous reports that have inferred that elevated BCAAs in diabetic patients are caused, in part, by reduced catabolism. In summary, the integration of metabolomics and transcriptomics data via integrative pathway mapping has facilitated the identification and contextualization of biomarkers that, presuming further analytical and biological validation, may be useful in future T2D clinical studies by identifying patient populations that share common disease pathophysiology and therefore may identify those patients that may respond better to a particular class of anti-diabetic drugs.

Investigation of metabolic pathways from gut microbiome analyses regarding type 2 diabetes mellitus using artificial neural networks

Construction and Analysis of Functional Networks in the Gut Microbiome of Type 2 Diabetes Patients.

Classification of Microbiome Data from Type 2 Diabetes Mellitus Individuals with Deep Learning Image Recognition

Functional alterations and predictive capacity of gut microbiome in type 2 diabetes

Identification of Key Gene Pathways and Coexpression Networks of Islets in Human Type 2 Diabetes.

Identification of Microbiota Biomarkers With Orthologous Gene Annotation for Type 2 Diabetes

Targeting metabolic pathways: a novel therapeutic direction for type 2 diabetes

Predicting the role of the human gut microbiome in type 1 diabetes using machine-learning methods

Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes

The role of the gut microbiota in the pathogenesis and therapy of type 2 diabetes mellitus

A system biological approach to investigate the genetic profiling and comorbidities of type 2 diabetes

A network perspective on the ecology of gut microbiota and progression of type 2 diabetes: Linkages to keystone taxa in a Mexican cohort

Systems Biology of Human Microbiome for the Prediction of Personal Glycaemic Response

Role of gut microbiota in type 2 diabetes pathophysiology

Dysbiosis signatures of gut microbiota and the progression of type 2 diabetes: a machine learning approach in a Mexican cohort

Metabolomics in human type 2 diabetes research

The potential role of gut microbiota in the pathogenesis of type 2 diabetes mellitus via epigenetics and inflammasome.

Metabolic modelling reveals increased autonomy and antagonism in type 2 diabetic gut microbiota

The Role of Gut Microbiota in the Development of Type 2 Diabetes Mellitus

Integrated 16S rRNA Sequencing, Metagenomics, and Metabolomics to Characterize Gut Microbial Composition, Function, and Fecal Metabolic Phenotype in Non-obese Type 2 Diabetic Goto-Kakizaki Rats

Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis